Literature DB >> 11490372

Nuclear factor-kappa B is upregulated in colorectal cancer.

D S Lind1, S N Hochwald, J Malaty, S Rekkas, P Hebig, G Mishra, L L Moldawer, E M Copeland, S Mackay.   

Abstract

BACKGROUND: Chemoresistance may involve the anti-apoptotic transcriptional regulator, nuclear factor-kappa B (NF-kappa B). The purpose of this study was to determine whether chemotherapy induces NF-kappa B activation in a human colon cancer cell line (SW48) and whether NF-kappa B is constitutively activated in colorectal cancer.
METHODS: SW48 cells were incubated with gemcitabine hydrochloride (Gemzar) in the presence and absence of the 26s proteasome inhibitor, MG132, and NF-kappa B binding (electrophoretic mobility shift assay), DNA synthesis (tritiated thymidine uptake), cell viability (3-[4,5-dimethylthiazol-2-yl]-diphenyl-tetrazolium bromide assay), and apoptosis (caspase-3 activity) were measured at 24 hours. NF-kappa B binding (electrophoretic mobility shift assay) was also assayed in 10 colorectal cancer tumors.
RESULTS: SW48 cells demonstrated constitutive NF-kappa B binding that was enhanced by gemcitabine hydrochloride in a dose-dependent manner. MG132 inhibited NF-kappa B binding and enhanced gemcitabine hydrochloride's inhibition of DNA synthesis (gemcitabine hydrochloride = 73% +/- 1.4% vs gemcitabine hydrochloride + MG132 = 6% +/- 0.4%, P <.05), cell killing (gemcitabine hydrochloride = 87% +/- 2.0 vs gemcitabine hydrochloride + MG132 = 25% +/- 1.3%, P <.05), and caspase-3 activity (gemcitabine hydrochloride = 870 +/- 17.4 vs gemcitabine hydrochloride + MG132 = 1075 +/- 20.4, P <.05). NF-kappa B binding was increased in 8 of 10 colorectal cancer tumors compared with adjacent normal mucosa.
CONCLUSIONS: Gemcitabine hydrochloride enhances NF-kappa B binding in a colorectal cancer cell line, whereas inhibition of NF-kappa B enhances gemcitabine hydrochloride's antitumor activity. NF-kappa B is also activated in human colorectal cancer. NF-kappa B may identify chemoresistant tumors, whereas inhibition of NF-kappa B may be a novel, biologically based therapy. (Surgery 2001;130:363-9).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11490372     DOI: 10.1067/msy.2001.116672

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  79 in total

1.  Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer.

Authors:  Shing Cheng Tan; Mohd Shafi'i Mohd Suzairi; Abdul Aziz Ahmad Aizat; Mustapha Mohd Aminudin; Mohd Shahpudin Siti Nurfatimah; Venkata Murali Krishna Bhavaraju; Biswa Mohan Biswal; Ravindran Ankathil
Journal:  Med Oncol       Date:  2013-08-31       Impact factor: 3.064

2.  Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis.

Authors:  Jasleen Shant; Kunrong Cheng; Bernard S Marasa; Jian-Ying Wang; Jean-Pierre Raufman
Journal:  Exp Cell Res       Date:  2008-11-20       Impact factor: 3.905

Review 3.  Potential beneficial effects of butyrate in intestinal and extraintestinal diseases.

Authors:  Roberto Berni Canani; Margherita Di Costanzo; Ludovica Leone; Monica Pedata; Rosaria Meli; Antonio Calignano
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

4.  Autophagosomal IkappaB alpha degradation plays a role in the long term control of tumor necrosis factor-alpha-induced nuclear factor-kappaB (NF-kappaB) activity.

Authors:  Amy Colleran; Aideen Ryan; Angela O'Gorman; Coralie Mureau; Catherine Liptrot; Peter Dockery; Howard Fearnhead; Laurence J Egan
Journal:  J Biol Chem       Date:  2011-03-31       Impact factor: 5.157

Review 5.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

6.  Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB.

Authors:  Hiroyuki Mutoh; Hiroko Hayakawa; Hirotsugu Sakamoto; Kentaro Sugano
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

7.  Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.

Authors:  Sanjeev Shukla; Gregory T MacLennan; Pingfu Fu; Jigar Patel; Susan R Marengo; Martin I Resnick; Sanjay Gupta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

8.  Glycine- and proline-rich glycoprotein regulates the balance between cell proliferation and apoptosis for ACF formation in 1,2-dimethylhydrazine-treated A/J mice.

Authors:  Sei-Jung Lee; Kye-Taek Lim
Journal:  Mol Cell Biochem       Date:  2009-01-31       Impact factor: 3.396

9.  Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.

Authors:  Magdalena Zajac; Gonzalo Gomez; Javier Benitez; Beatriz Martínez-Delgado
Journal:  BMC Med Genomics       Date:  2010-10-04       Impact factor: 3.063

10.  A distinctive physiological role for IkappaBbeta in the propagation of mitochondrial respiratory stress signaling.

Authors:  Gopa Biswas; Weigang Tang; Neal Sondheimer; Manti Guha; Seema Bansal; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2008-02-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.